Truist raised the firm’s price target on Medtronic to $84 from $78 and keeps a Hold rating on the shares. The company reported a “solid” Q2 earnings beat and raise with a third consecutive quarter of delivering mid-single-digit top-line and “modest” EPS upside, though results likely cleared an “admittedly low bar”, the analyst tells investors in a research note. Medtronic’s new product cadence heading into the second half of FY24 and FY25 should support sustained mid-single-digit organic growth, Truist adds, noting that it has also increased its FY25 organic revenue and EPS estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MDT:
- Early notable gainers among liquid option names on November 21st
- Medtronic sees Q3 organic revenue growth 4%-4.5%
- Medtronic (NYSE:MDT) Gains on Healthy Q2 Performance
- Options Volatility and Implied Earnings Moves Today, November 21, 2023
- Medtronic raises FY24 EPS view to $5.13-$5.19 from $5.08-$5.16, consensus $5.12